Results 31 to 40 of about 20,836,880 (230)

Adaptation of New Oral Anticoagulants for Warfarin Anticoagulated Patient with Traumatic Ongoing Hemorrhage [PDF]

Journal of Acute Care Surgery, 2018
The traditional drug for anticoagulation in those with a high risk of thrombosis is a vitamin K antagonist, such as warfarin. On the other hand, this drug has several limitations and hemorrhagic complications.
Jin Bong Ye, Young Hoon Sul, Jin Young Lee, Seung Je Go, Jung Hee Choi   +4 more
doaj   +1 more source

Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background This study aimed to compare percutaneous left atrial appendage occlusion (LAAO) with non‐vitamin K antagonist oral anticoagulants among patients with atrial fibrillation. Methods and Results Using a US administrative database, 562 850 patients
Peter A. Noseworthy, Holly K. Van Houten, Harlan M. Krumholz, David M. Kent, Neena S. Abraham, Jonathan Graff‐Radford, Mohamad Alkhouli, Henry J. Henk, Nilay D. Shah, Bernard J. Gersh, Paul A. Friedman, David R. Holmes, Xiaoxi Yao   +12 more
doaj   +1 more source

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.

PLoS ONE, 2022
AimsA Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with ...
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere   +10 more
doaj   +2 more sources

Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?

Российский кардиологический журнал, 2019
Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with ...
N. N. Kryukov, E. V. Sayutina, A. M. Osadchuk, M. A. Osadchuk   +3 more
doaj   +1 more source

Non-vitamin K antagonist oral anticoagulants and heart failure

Archives of Cardiovascular Diseases, 2016
Thromboembolism contributes to morbidity and mortality in patients with heart failure (HF), and atrial fibrillation (AF) is one of the main factors promoting this complication. As they share many risk factors, HF and AF frequently coexist, and patients with both conditions are at a particularly high risk of thromboembolism.
Isnard, R., Bauer, F., Cohen-Solal, A., Damy, T., Donal, Erwan, Galinier, M., Hagège, A., Jourdain, P., Leclercq, Christophe, Sabatier, Rodolphe, Trochu, Jean-Noël, Cohen, A.   +11 more
openaire   +3 more sources

Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants [PDF]

, 2017
Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major adverse events and medication adherence is central to achieve good ...
Lane, Deirdre A, Lip, Gregory, Lane, Deirdre, Stefania, Basili, Raparelli, Valeria, Lane, Deirdre A., Lip, Gregory Y. H., Lip, Gregory Y H, Basili, Stefania, Proietti, Marco, Cangemi, Roberto   +10 more
core   +1 more source

Safety of endovascular thrombectomy in patients receiving non-vitamin K antagonist oral anticoagulants [PDF]

, 2016
Background and Purpose—Prospective data on the safety of endovascular thrombectomy in acute stroke patients on non– vitamin K antagonist oral anticoagulants are lacking. Methods—Prospective multicenter observational study.
Khan, S, Groeschel, K, Seidel, G, Veltkamp, R, Purrucker, JC, Heuschmann, PU, Dziewas, R, Ringleb, PA, Wolf, M, Kleinschnitz, C, Hennerici, MG, Rizos, T, Binder, A, Neumann-Haefelin, T, Lobotesis, K, Poli, S, Haas, K   +16 more
core   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality

Global Heart, 2020
Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for
Ezequiel J. Zaidel, Xinyi Leng, Abiodun Moshood Adeoye, Ferdous Hakim, Biraj Karmacharya, Asim Katbeh, Lis Neubeck, Stephanie Partridge, Pablo Perel, Mark D. Huffman, Mariachiara Di Cesare   +10 more
doaj   +1 more source

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios

International Journal of Cardiology: Heart & Vasculature, 2018
Atrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia.
Ting-Yung Chang, Jo-Nan Liao, Tze-Fan Chao, Jennifer Jeanne Vicera, Chin-Yu Lin, Ta-Chuan Tuan, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Fa-Po Chung, Shih-Ann Chen   +11 more
doaj   +1 more source